Qiagen Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/24/2026)
| Balance Sheet | Total Assets | 6,295,960,000.00 | ROE | 60.01 % |
| Balance Sheet | Total Equity | 3,778,150,000.00 | ROA | 6.75 % |
| Cashflow | Capital Expenditures | -201,049,000.00 | P/FCF | 18.86 |
| Cashflow | Free Cash Flow | 453,276,992.00 | – | – |
| Cashflow | Operating Cash Flow | 654,326,000.00 | P/CF | 13.07 |
| Income | Earnings per Share (diluted) | 1.94 | Div. Yield | 0.61 % |
| Income | Net Income | 424,880,000.00 | P/E | 21.20 |
| Income | Shares Outstanding | 207,936,000.00 | P/B | 2.26 |
| Income | Total Revenue | 2,090,000,000.00 | P/S | 4.09 |
Ratios calculated on: 10/14/2026
Company Description
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions. It also provides Ingenuity Variant Analysis, a cloud-based platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence-based decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and select gene-and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products. In addition, the company offers instrumentation systems for laboratories. Its automation platforms include QIAsymphony, a modular system; GeneReader NGS System, a sample to insight NGS solution for laboratories to deliver actionable results; QIAcube robotic workstations, which provides versatile solutions for automated sample processing; QIAxcel for nucleic acid separation; QIAgility, a benchtop instrument for PCR setup; and ESEQuant instruments that enable optical measurement for point of need molecular testing in physician practices, emergency rooms, remote areas, and other applications. It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has a collaboration with Bristol-Myers Squibb to develop gene expression profiles for immuno-oncology therapies. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.qiagen.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more